Treatment
Dose Escalation clinical trials
We’re tracking 186 recruiting studies that include Dose Escalation, each written for real people, not researchers, below.
Recruiting studies
- NCT06461793RecruitingPhase 2
Higher dose radiation with hormone therapy for high-risk prostate cancer
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT06958328RecruitingPhase 3
Testing higher dose radiation for locally advanced pancreatic cancer
This trial tests if a higher dose of radiation therapy can help people with locally advanced pancreatic cancer after they've had 4–6 months of chemotherapy. It aims to improve cancer control without significantly increasing side effects.
Gilbert, ArizonaAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT06461819RecruitingPhase 2
Higher radiation dose for low-to-intermediate prostate cancer
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
SeoulAges 20 years+ - NCT05613894RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT04649125Recruiting
Single-shot versus multi-day palliative radiation for metastatic cancer
This trial compares a single treatment session (one-fraction radiation) versus the usual multiple sessions (multi-fraction radiation) to help relieve symptoms from metastatic cancer. It may help your care team find the most effective and practical schedule for symptom control.
Saint Leonards, New South WalesAges Any age - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT06169371RecruitingTeam says not enrollingPhase 4
Abemaciclib dose escalation for early breast cancer
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
Chicago, IllinoisAges 18 years+ - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT04802603Recruiting
Focused spine radiation for limited spread to the spine
This trial tests a stronger, carefully measured form of radiation aimed at a small number of spots where cancer has spread to the spine. It may help control pain and tumor growth while protecting the spinal cord.
Miami, FloridaAges 18 years+ - NCT04020276Recruiting
Adaptive MRI radiation for liver metastases
This study tests a radiation treatment that uses real-time MRI (an imaging scan) to guide the dose for liver metastases. It may help control tumors while aiming to better protect nearby healthy liver tissue.
Madison, WisconsinAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT07641426RecruitingPhase 1/Phase 2
CID-103 Treatment for Kidney Transplant Rejection
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT02852213RecruitingPhase 1
Dose-check study for children with AADC deficiency using brain surgery
This Phase 1 trial tests how safe different treatment doses are for children with AADC deficiency, using MRI-guided brain surgery. It may help improve movement and developmental progress after standard medicines did not work well enough.
San Francisco, CaliforniaAges 2 years+ - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06234397RecruitingPhase 1
Study of BH3120 with or without pembrolizumab for advanced cancers
This trial tests a new drug, BH3120, alone or with pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the combination can help your immune system fight cancer more effectively.
Tampa, FloridaAges 18 years+ - NCT07344818RecruitingEarly Phase 1
CAR-T cell therapy targeting CD19 and CD20 for hard-to-treat B-cell lymphoma
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04815694Recruiting
MRI-guided radiotherapy for rectal cancer
This trial tests whether using MRI scans to guide radiotherapy can improve treatment for people with a certain type of rectal cancer. It focuses on patients whose tumors have not spread to other parts of the body and who have specific tumor features seen on MRI.
Roma, RomaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Dose Escalation?
- Yes. Clin2 currently lists 186 recruiting studies that include Dose Escalation, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dose Escalation trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dose Escalation an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dose Escalation or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.